Dr. Papadimitrakopoulou on Treatment Options for EGFR-Mutant NSCLC | OncLive

Dr. Papadimitrakopoulou on Treatment Options for EGFR-Mutant NSCLC

June 2, 2017

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

There are multiple options for first-line therapy for patients with EGFR-mutant NSCLC, explains Papadimitrakopoulou. The first-generation EGFR tyrosine kinase inhibitors (TKI’s) are actively being used in the community and academic setting.

Second-line therapy for patients who have developed a resistance to first-generation EGFR TKI’s has been dominated by the FDA approval of osimertinib (Tagrisso), states Papadimitrakopoulou. Osimertinib has become the standard of care for patients whose tumors have developed a T790M mutation.


x